A REVIEW ON MUCORMYCOSIS BLACK AND WHITE PHASE OF FUNGUS

Authors

  • SAKSHI KULKARNI Department of Pharmaceutical Quality Assurance, M.G.V’s Pharmacy College, Panchavati, Nashik, Maharashtra, India. https://orcid.org/0000-0001-8075-4344
  • ANUJA BHOSALE Department of Pharmaceutical Chemistry, M.G.V.’s Pharmacy College, Panchavati, Nashik, Maharashtra, India.

DOI:

https://doi.org/10.22159/ajpcr.2022.v15i6.44641

Keywords:

Mucormycosis, Black fungus, MRI, Rhino-orbito -cerebral, Mucoraceae

Abstract

Mucormycosis started during COVID 19 when patients were treated with number of steroids oxygen, that further lead to increase in diabetes mellitus which was main cause of mucormycosis increase in black fungus further caused rhino-orbito-cerebral mucormycosis and angio invasive behavior of fungal hype that is from Mucoraceae family is main cause of the infection increases rapidly also damages the facial tissues vigorously uncontrolled diabetes, immunosuppressive, steroids poor glycemic control are main causes MRI is a technique that is been used for observing the growth of fungal hype from Epidermiological data its been proven that the mucormycosis is been spreading in countries such as India, Nepal, and Bangladesh rapidly its serious health concern in future.

Downloads

Download data is not yet available.

References

Benedict K, Jackson BR, Chiller T, Beer KD. Estimation direct healthcare costs of fungal diseases in the United States. Clin Infect Dis 2019;68:1791-97. doi: 10.1093/cid/ciy776, PMID 30204844

Sharma K, Banstola A, Parajuli RR. Assessment of COVID-19 pandemic in Nepal: A lockdown scenario analysis. Front Public Health 2021;9:599280. doi: 10.3389/fpubh.2021.599280, PMID 33898371

Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: A review of 929 reported cases. Clin Infect Dis 2005;41:634-53. doi: 10.1086/432579, PMID 16080086

Kontoyiannis DP, Lewis RE. How I treat mucormycosis. Blood 2011;118:1216-24. doi: 10.1182/blood-2011-03-316430

Ino K, Nakase K, Nakamura A, Nakamori Y, Sugawara Y, Miyazaki K et al. Mucormycosis on a polymerase chain reaction (PCR) diagnosis in patients with malignancies. Intern Med 2017;56:707-11. doi: 10.2169/ internalmedicine.56.7647, PMID 28321075

Tissot F, Agrawal S, Pagano L, Petrikkos G, Groll AH, Skiada A et al. ECIL-6 guidelines for the treatment of candidiasis, aspergillosis and mucormycosis found in leukemia and hematopoietic stem cell transplant patients. Haematologica 2017;102:433-44. doi: 10.3324/ haematol.2016.152900, PMID 28011902

Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based therapy significantly increased in mortality among patients with hematologic malignancy who have Zygomycosis. Clin Infect Dis 2008;47:503-9. doi: 10.1086/590004, PMID 18611163

Wiederhold NP. Pharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infections. Clin Pharmacol 2016;8:1-8. doi: 10.2147/CPAA.S60933, PMID 26730212

Hoang K, Abdo T, Reinersman JM, Lu R, Higuita NI. A case of invasive pulmonary mucormycosis resulting short courses of corticosteroids in a well-controlled diabetic patient. Med Mycol Case Rep 2020;29:22-4. doi: 10.1016/j.mmcr.2020.05.008, PMID 32547914

Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SC, Dannaoui E, Hochhegger B, et al. Mucormycosis, Global guideline for the diagnosis and management of mucormycosis: An initiative of the European confederation of medical mycology in cooperation with mycoses study group education and research consortium. Lancet Infect Dis 2019;19:405-21. doi: 10.1016/S1473-3099(19)30312-3, PMID 31699664

Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in patient with COVID-19. Am J Emerg Med 2021;42:264. e5-8. doi: 10.1016/j.ajem.2020.09.032, PMID 32972795

Artis WM, Fountain JA, Delcher HK, Jones HE. A mechanism of susceptibility to mucormycosis and ketoacidosis iron availability. Diabetes 1982;31:1109-14.

Zaman K, Rudramurthy SM, Das A, Panda N, Honnavar P, Kaur H, et al. Molecular diagnosis of rhino-orbito-cerebral mucormycosis from tissue samples. J Med Microbiol 2017;66:1124-29. doi: 10.1099/ jmm.0.000560, PMID 28792370

John TM, Jacob CN, Kontoyiannis DP. When uncontrolled diabetes mellitus and mucormycosis. J Fungi (Basel) 2021;7:298

Joshi AR, Muthe MM, Patankar SH, Athawale A, Achhapalia Y. CT and MRI findings of invasive mucormycosis and COVID-19: Experience from a single center India. AJR Am J Roentgenol 2021;217:1431-2. doi: 10.2214/AJR.21.26205, PMID 34161127

Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. Lancet 2003;362:1828-38. doi: 10.1016/S0140- 6736(03)14904-5, PMID 14654323

Published

07-06-2022

How to Cite

KULKARNI, S., and A. BHOSALE. “A REVIEW ON MUCORMYCOSIS BLACK AND WHITE PHASE OF FUNGUS”. Asian Journal of Pharmaceutical and Clinical Research, vol. 15, no. 6, June 2022, pp. 17-18, doi:10.22159/ajpcr.2022.v15i6.44641.

Issue

Section

Review Article(s)